{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:17:20Z","timestamp":1793175440042,"version":"4.5.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2023206042"],"award-info":[{"award-number":["H2023206042"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Rifaximin (RFX) is recommended for the treatment of hepatic encephalopathy (HE). However, evidence on whether RFX application could yield additional benefits for preventing HE in patients with cirrhosis is limited. In this study, we aimed to assess the safety and efficacy of RFX in preventing HE. We conducted a systematic search of randomized controlled trials to evaluate the use of RFX by analyzing HE incidence, hospitalization, all-cause mortality, and adverse events. Compared with the control group, RFX had a beneficial effect on the primary prevention of HE (RR\u2009=\u20090.58, 95% CI: 0.50\u20130.68), with noncomparable effects to NADs (including lactulose and lactitol, RR\u2009=\u20090.65, 95% CI: 0.38\u20131.11), but more effective than placebo (RR\u2009=\u20090.57, 95% CI: 0.47\u20130.69). After more than 1 month of RFX treatment, the risk of HE decreased significantly (RR\u2009=\u20090.55, 95% CI: 0.47\u20130.65). In secondary prevention of HE, RFX decreased the recurrence risk (RR\u2009=\u20090.49, 95% CI: 0.40\u20130.61). RFX helped to reduce the incidence of HE after transjugular intrahepatic portosystemic stent shunt (TIPSS) (RR\u2009=\u20090.70, 95% CI: 0.51\u20130.96). In terms of adverse effects, RFX was associated with a lower risk of diarrhea than NADs (RR\u2009=\u20090.04, 95% CI: 0.00\u20130.25). So, RFX therapy is effective and well-tolerated in preventing HE, and can be used as the first choice in the prophylaxis of HE after TIPSS.<\/jats:p>","DOI":"10.1371\/journal.pone.0323359","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:28:57Z","timestamp":1747416537000},"page":"e0323359","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Yangyang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-0674","authenticated-orcid":true,"given":"Yadong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"6","key":"pone.0323359.ref001","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jhep.2020.07.013","article-title":"Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy","volume":"73","author":"CF Rose","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"pone.0323359.ref002","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/gutjnl-2019-320221","article-title":"Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension","volume":"69","author":"D Tripathi","year":"2020","journal-title":"Gut"},{"issue":"5","key":"pone.0323359.ref003","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"P Jepsen","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"pone.0323359.ref004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-022-00366-6","article-title":"Hepatic encephalopathy","volume":"8","author":"D H\u00e4ussinger","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"pone.0323359.ref005","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"R Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"pone.0323359.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.04.034","article-title":"Hepatic Encephalopathy: Current and Emerging Treatment Modalities","volume":"20","author":"MA Fallahzadeh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"pone.0323359.ref007","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The Use of Rifaximin in Patients With Cirrhosis","volume":"74","author":"P Caraceni","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"pone.0323359.ref008","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/liv.15510","article-title":"Diagnosis and management of hepatic encephalopathy: The French recommendations","volume":"43","author":"D Thabut","year":"2023","journal-title":"Liver Int"},{"issue":"3","key":"pone.0323359.ref009","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","author":"Liver European Association for the Study of the","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0323359.ref010","first-page":"5675","article-title":"Study to know the rifaximin efficacy in hepatic encephalopathy prevention in cirrhosis of liver","volume":"5","author":"F Munir","year":"2018","journal-title":"Indo Am J P Sci"},{"key":"pone.0323359.ref011","doi-asserted-by":"crossref","first-page":"696065","DOI":"10.3389\/fphar.2021.696065","article-title":"Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy","volume":"12","author":"X Han","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0323359.ref012","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"pone.0323359.ref013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"N Bass","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0323359.ref014","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2004.12.028","article-title":"Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study","volume":"42","author":"O Riggio","year":"2005","journal-title":"J Hepatol"},{"issue":"8","key":"pone.0323359.ref015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","article-title":"Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study","volume":"34","author":"A Sanyal","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"pone.0323359.ref016","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jgh.12970","article-title":"Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease","volume":"30","author":"N Khokhar","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"pone.0323359.ref017","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gutjnl-2014-308521","article-title":"Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed","volume":"64","author":"S Maharshi","year":"2015","journal-title":"Gut"},{"key":"pone.0323359.ref018","first-page":"3015891","article-title":"Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding","volume":"2018","author":"F Higuera-de-la-Tijera","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"3","key":"pone.0323359.ref019","first-page":"843","article-title":"Compare the Efficacy of Low versus High Dose of Rifaximin for Primary Prophylaxis of Protosystemic Encephalopathy","volume":"14","author":"N Habib","year":"2020","journal-title":"Pak J Med Health Sci"},{"issue":"5","key":"pone.0323359.ref020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/M20-0202","article-title":"The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt\u00a0: A Randomized Controlled Trial","volume":"174","author":"C Bureau","year":"2021","journal-title":"Ann Intern Med"},{"issue":"10","key":"pone.0323359.ref021","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jhbp.947","article-title":"Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial","volume":"28","author":"KAM Glal","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"pone.0323359.ref022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12072-020-10117-y","article-title":"Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis","volume":"15","author":"X Zeng","year":"2021","journal-title":"Hepatol Int"},{"issue":"2","key":"pone.0323359.ref023","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jceh.2021.08.010","article-title":"Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial","volume":"12","author":"DL Praharaj","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"pone.0323359.ref024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in vitro and in vivo antibacterial activity--a review","author":"ZD Jiang","year":"2005","journal-title":"Chemotherapy"},{"issue":"5","key":"pone.0323359.ref025","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","volume":"72","author":"JS Bajaj","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0323359.ref026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/flgastro-2022-102221","article-title":"Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-\u03b1 treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)","volume":"14","author":"RJ Aspinall","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"11","key":"pone.0323359.ref027","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/hep4.1425","article-title":"Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis","volume":"3","author":"EB Tapper","year":"2019","journal-title":"Hepatol Commun"},{"issue":"6","key":"pone.0323359.ref028","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5152\/tjg.2023.22575","article-title":"Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis","volume":"34","author":"A Elmoursi","year":"2023","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"pone.0323359.ref029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.15403\/jgld-4508","article-title":"Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis","volume":"32","author":"Z Ahmed","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"pone.0323359.ref030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.dld.2018.11.035","article-title":"Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF)","volume":"51","author":"S Montagnese","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"7","key":"pone.0323359.ref031","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for Liver Cirrhosis 2020","volume":"56","author":"H Yoshiji","year":"2021","journal-title":"J Gastroenterol"},{"issue":"6","key":"pone.0323359.ref032","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1128\/AAC.00548-13","article-title":"Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile","volume":"57","author":"JS Huang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0323359.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186120","article-title":"Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients","volume":"12","author":"JY Chang","year":"2017","journal-title":"PLoS One"},{"key":"pone.0323359.ref034","doi-asserted-by":"crossref","first-page":"761192","DOI":"10.3389\/fcimb.2021.761192","article-title":"Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome","volume":"11","author":"X Yu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"pone.0323359.ref035","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/cid\/cix918","article-title":"Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin","volume":"66","author":"E Reigadas","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:29:05Z","timestamp":1747416545000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323359"}},"subtitle":[],"editor":[{"given":"Peter","family":"Starkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323359","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}